echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Fudan Zhangjiang oral JAK1 inhibitor approved for Phase II clinical use in the treatment of atopic dermatitis

    Fudan Zhangjiang oral JAK1 inhibitor approved for Phase II clinical use in the treatment of atopic dermatitis

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Article source: Medical Rubik's Cube Info

    On November 6, Fudan Zhangjiang issued an announcement stating that its Class 1 new drug FZJ-003 capsule is an oral JAK1 selective inhibitor (specification: 25mg, 50mg) for the treatment of moderate to severe atopic dermatitis Phase II clinical trial application Accepted by the Food and Drug Administration
    This is the new indication phase II clinical trial of FZJ-003 capsule during the phase I clinical trial for the treatment of rheumatoid arthritis


    Atopic dermatitis (AD) is a chronic inflammatory disease, usually in the form of a skin rash
    According to past data from WHO, at least 250 million people worldwide are currently suffering from AD, and the incidence of AD patients in China is about 10%

    At present, 40% of the affected population are moderate to severe AD patients.
    The rash may cover most parts of the body, accompanied by intense and persistent itching, dry skin, cracking, redness or darkening, crusting or oozing, etc.

    Itching usually causes sleep disturbances, which can seriously affect the quality of life


    At present, biological agents dominate the field of treatment of moderate to severe AD.
    Oral JAK preparations have also shown amazing effects in clinical studies, and they have natural advantages in terms of onset time and usage

    There is no selective inhibitor of JAK1 on the market in China


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.